Insights

  • Date

  • Content Type

  • Reset

Blog

Risk Management Plans for ATMPs

13.06.21

by Maria Schacker

ATMPs are a relatively novel class of medicinal products with anew and very unique set...

Read More

Blog

Neutralizing Antibody Assay Development – a key consideration for immunogenicity packages

01.06.21

by Jennifer Sales

Neutralising Antibodies, or NAbs, are a subclass of Anti-Drug Antibodies that may be formed during...

Read More

Blog

Better late than never? What developers of SARS-CoV-2 vaccines in early-to -late-stage development should consider

12.05.21

by Michael Pfleiderer, Ilona Baraniak and Ciaran Greene

Unfortunately, as of today the ongoing pandemic is still far...

Read More

Blog

Wake up the Sleeping Beauty – Transposons in gene therapy: How do they compare to other genome modifying tools?

04.05.21

by Ewa Janosz

Gene therapy is currently a quickly developing field. Except from commonly known viral vectors and...

Read More

Blog

Requests for proposals – Get the best value when asking for services

26.04.21

by Timo Liebig

You need a service provider, but which one suits your needs best? Read here how...

Read More

Blog

AAV gene therapy development: Immunogenicity and safety aspects

02.03.21

by Eveline Molocea and Jörg Schneider

Adeno-associated virus (AAV) is a dominant gene delivery platform that matured in...

Read More